Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
about
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome"Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesSpecific involvement of pilus type 2a in biofilm formation in group B Streptococcus.Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.Identification of a group B streptococcal fibronectin binding protein, SfbA, that contributes to invasion of brain endothelium and development of meningitis.Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.Regulation of virulence by a two-component system in group B streptococcus.Parasite Carbohydrate Vaccines.A serotype VIII strain among colonizing group B streptococcal isolates in Boston, Massachusetts.Regulation of cell component production by growth rate in the group B Streptococcus.Localization of surface immunogenic protein on group B streptococcus.Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccinesProtection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.Group B streptococcal serine-rich repeat proteins promote interaction with fibrinogen and vaginal colonizationNeonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.Maternal vaccination: moving the science forward.Antibody response specific to the capsular polysaccharide is impaired in Streptococcus suis serotype 2-infected animals.Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant womenSerine-rich repeat proteins and pili promote Streptococcus agalactiae colonization of the vaginal tract.Group B streptococcal infection and activation of human astrocytes.Bacterial induction of Snail1 contributes to blood-brain barrier disruption.The changing face of childhood meningitis.A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement PathwaysVariation in the group B Streptococcus CsrRS regulon and effects on pathogenicity.Inactivation of the alpha C protein antigen gene, bca, by a novel shuttle/suicide vector results in attenuation of virulence and immunity in group B Streptococcus.Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.Carbohydrates and T cells: a sweet twosome.Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathwaysFunctional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells.A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing.CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine developmentImmune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.BsaB, a novel adherence factor of group B Streptococcus.Carbohydrates as T-cell antigens with implications in health and disease.Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus.
P2860
Q22066389-47F48BBA-D9A0-4DC6-9745-FDBF3B49803FQ26746887-DBCFAF99-1CA8-4C18-A274-5C1813CF7BB1Q33532629-B40E6AEF-ECAF-4FD8-9B70-0A526BF12ED4Q33591531-DF0281C6-67EC-46FC-A7CD-33407AE9AFB9Q33603050-F7C2659B-469D-4201-97F8-D176D9269125Q33703237-03B9E52B-DD35-4C01-B0FF-4B5AF32EBF8CQ33753897-45C9B80E-CD22-40B1-B846-9F8B241DE5DFQ33758224-A40D6092-0C39-4B0F-8B12-E5D98B2A5944Q33785863-D591F683-E1B9-4C09-BD85-3122614179EEQ33963795-3CAF8AFE-2A86-43B5-AD25-38B895729252Q33992857-15E25787-63E0-46A1-984F-1EB1D3EE6960Q34008722-81E3ECFC-10A4-44CB-99BD-74E584EF36E7Q34049012-EEAF0F0C-76C6-4559-9FB4-F0F7F5C353E9Q34130285-14BFA425-9FBC-47F8-B78B-67E97F694C6BQ34235531-1CF73600-CED5-4865-B757-35D0A222017BQ34315633-901F4D49-A42B-4A1D-A68F-131DC618B8C0Q34532914-EF84A4A7-E64D-41DC-A8DF-376FE04CDF1CQ34630952-125C4EAC-F15B-45AD-BF30-31FA2AFA9915Q34890075-19EAE5C9-9A07-40E0-B230-64C9FB573E70Q35470773-144DB573-7859-4D49-918D-927145B2C3F9Q35481196-404DA97B-3BA7-4953-A88C-14356E266900Q35489205-53990AA9-E57F-482D-BC37-B3451B90CAEBQ35598620-C303A431-2FE1-4210-A020-F784E8A2A3B1Q35648179-2358D284-EEBE-4E2C-AE88-AA8C9243854EQ35836082-84A78AFC-C743-406F-B251-A1A85AC829DDQ35839171-FFF0BEDE-A22B-400E-99D8-2C9AE3E3CD86Q36351293-02D9D1BC-9450-4AC8-B466-8417E59F0E14Q36382263-2CE1A51D-5FF3-4A48-94E4-897C5E7DB1E1Q36483768-86F49585-7CD1-4EA8-B03A-F652F0626141Q36723548-DE0D88B6-213E-413A-85D2-A1B5AE98EDFDQ37074015-7B77F79F-559E-48BB-994E-319A455754BAQ37118132-025A3DB0-5BC5-4D3D-8743-8D4F1FF9F58DQ37123791-5B7FC2B9-5A5F-4721-9220-0D910CBC1CD0Q37242957-7FAC39E9-5DB0-40BE-8A6A-0E7C7FC4ABFDQ37263526-915EC491-B141-4C01-8DA3-FD2E6AD6BA94Q37302067-45CF0B3A-A4F4-4CD4-A238-660E83A410CDQ37361495-6B9CB331-0609-438A-AE21-6F29E83EAACFQ37643871-260EB722-0FCA-460F-BAC8-A574217DAB60Q38847198-F3D4CDF0-0E56-4ED4-9969-B5B98C9DD0AFQ39829516-584500BB-2156-4204-9E24-69BFCCDCAB0B
P2860
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@ast
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@en
type
label
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@ast
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@en
prefLabel
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@ast
Stimulation of protective anti ...... anus toxoid conjugate vaccine.
@en
P2093
P2860
P1476
Stimulation of protective anti ...... tanus toxoid conjugate vaccine
@en
P2093
A K Rodewald
D L Kasper
H J Jennings
L C Paoletti
M R Wessels
P2860
P304
P407
P577
1993-11-01T00:00:00Z